Valuation: Oncopeptides AB

Market Cap 685M 67.75M 61.51M 56.82M 51.26M 96.77M 6.33B 100M 271M 3.42B 254M 249M 10.79B P/E 2026 *
-3.77x
P/E 2027 * -7.7x
Enterprise Value 751M 74.29M 67.44M 62.29M 56.2M 106M 6.94B 110M 297M 3.75B 279M 273M 11.83B EV / Sales 2026 *
6.12x
EV / Sales 2027 * 3.21x
Free-Float
96.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.29%
1 week-2.16%
Current month+2.93%
1 month-0.92%
3 months+1.35%
6 months+0.58%
Current year-64.16%
1 week 1.7
Extreme 1.7
1.82
1 month 1.62
Extreme 1.619
1.88
Current year 1.26
Extreme 1.255
4.91
1 year 1.26
Extreme 1.255
5.8
3 years 1.1
Extreme 1.1
9.4
5 years 1.1
Extreme 1.1
50.84
10 years 1.1
Extreme 1.1
215
Manager TitleAgeSince
Chief Executive Officer 46 07/08/2023
Director of Finance/CFO 52 13/11/2023
Chief Tech/Sci/R&D Officer 54 01/09/2023
Director TitleAgeSince
Director/Board Member 65 01/01/2012
Director/Board Member 63 01/02/2017
Chairman 79 17/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/03/26 Free

Chief Technology Officer

3,000 0.0008%
18/03/26 Buy 14,631 0.0038%
17/03/26 Free

Investor Relations Manager

66 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.29%-2.16%-66.24%-80.25% 67.75M
+1.15%-2.81%+55.79%+71.12% 66.37B
+0.96%-1.51%+9.33%+91.30% 58.86B
+0.81%+0.42%+25.93%+86.56% 55.22B
+0.48%-2.53%+9.73%+121.14% 47.21B
-2.69%-6.38%+19.19%+25.79% 42.45B
-0.70%+4.93%+17.77%+45.03% 36.44B
-2.50%-15.73%+135.31%+662.73% 35.19B
-0.23%-2.11%+81.94%+57.03% 32.66B
-0.83%+1.98%-38.27%+390.98% 26.73B
Average -0.40%-2.31%+25.05%+147.14% 40B
Weighted average by Cap. -0.16%-2.18%+34.93%+146.95%

Financials

2026 *2027 *
Net sales 123M 12.14M 11.02M 10.18M 9.18M 17.34M 1.13B 18M 48.51M 612M 45.54M 44.58M 1.93B 234M 23.2M 21.06M 19.46M 17.55M 33.13M 2.17B 34.4M 92.72M 1.17B 87.04M 85.21M 3.7B
Net income -176M -17.41M -15.81M -14.6M -13.17M -24.87M -1.63B -25.82M -69.59M -878M -65.33M -63.95M -2.77B -107M -10.57M -9.59M -8.86M -8M -15.1M -987M -15.67M -42.24M -533M -39.65M -38.82M -1.68B
Net Debt 66M 6.53M 5.93M 5.48M 4.94M 9.33M 610M 9.69M 26.1M 329M 24.51M 23.99M 1.04B 68M 6.73M 6.11M 5.64M 5.09M 9.61M 629M 9.98M 26.9M 339M 25.25M 24.72M 1.07B
Projected Income Statement - Annual - Oncopeptides AB
Logo Oncopeptides AB
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Employees
71
Date Price Change Volume
18/11/26 SEK 1.724 -0.46% 48,777
17/11/26 SEK 1.732 -2.20% 2,045,543
16/11/26 SEK 1.771 +0.06% 1,322,372
13/11/26 SEK 1.770 +1.14% 3,247,293
12/11/26 SEK 1.750 -0.57% 2,284,702
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Oncopeptides AB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
1.732SEK
Average target price
2.700SEK
Spread / Average Target
+55.89%
  1. Stock Market
  2. Stocks
  3. ONCO Stock